Trial Profile
Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Varenicline (Primary)
- Indications Narcolepsy; Somnolence
- Focus Therapeutic Use
- Acronyms VESPA
- 21 Mar 2018 Status changed to discontinued due to insufficient patient enrollment, insufficient funds for completion
- 04 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 08 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.